PROJECT SUMMARY While dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) is recognized as the most sensitive examination for breast cancer detection, it has a substantial false positive rate and injection of gadolinium (Gd) contrast agents appears to have safety risks. Thus, alternatives to diagnosing breast cancer based on endogenous contrast are of growing interest. The overall goal of this proposal is to develop and evaluate a concurrent near-infrared spectroscopy (NIRS) and MRI imaging platform to explore whether the combined modality, which does not require contrast injection or involve ionizing radiation, can achieve acceptable diagnostic performance. The scientific premise of this proposal is underpinned by data from preliminary clinical studies that show MR-guided (MRg) NIRS adds much needed diagnostic specificity to breast MRI. We will also explore the exciting hypothesis that MRg NIRS serves as a surrogate for DCE MRI, and similar or the same diagnostic performance can be obtained by adding MRg NIRS to non-contrast MRI sequences, thereby eliminating the need for contrast injection. In preliminary studies, sensitivity, specificity, accuracy, and AUC of non-contrast MRI when combined with T2-guided NIRS were 94%, 100%, 96%, and 0.95, respectively, whereas these values were 94%, 63%, 88%, and 0.81 for DCE-MRI alone. This performance can be improved even further through direct regularization from images (DRI) methods and multi objective priors we propose to investigate in Aim 2. Equally important, we found the diagnostic performance of MRg NIRS is not degraded when CW signals are used to form NIRS images as long as subject specific scattering estimates are obtained (in Aim 1). Indeed, the practical utility of our current MRg NIRS system is undermined by its reliance on FD data, and the long, large-core fiber bundles that transmit light to/from data acquisition hardware to the breast inside the scanner. Elimination of these bulky weight-bearing fiber cables also simplifies the breast optical imaging interface, and opens the door to development of new options for the innovative, clinical-friendly design proposed in Aim 1. We will validate this platform iteratively in phantoms and volunteers (in Aim 3) and evaluate the new MRg NIRS + MRI technology when combined with and without contrast injection in a clinical study of 60 patients with breast abnormalities. The project leverages an extensive infrastructure we have developed for translational breast imaging where investigators from diagnostic radiology and biomedical engineering have collaborated to develop and evaluate advanced technology for more than two decades.
NIH ExPorter
NIH ExPorter